Acorah Software Products - Accounts Production 16.1.300 false true 31 July 2023 1 August 2022 false 1 August 2023 31 July 2024 31 July 2024 10289696 Mrs M Cumberbatch iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 10289696 2023-07-31 10289696 2024-07-31 10289696 2023-08-01 2024-07-31 10289696 frs-core:CurrentFinancialInstruments 2024-07-31 10289696 frs-core:ComputerEquipment 2024-07-31 10289696 frs-core:ComputerEquipment 2023-08-01 2024-07-31 10289696 frs-core:ComputerEquipment 2023-07-31 10289696 frs-core:ShareCapital 2024-07-31 10289696 frs-core:RetainedEarningsAccumulatedLosses 2024-07-31 10289696 frs-bus:PrivateLimitedCompanyLtd 2023-08-01 2024-07-31 10289696 frs-bus:FilletedAccounts 2023-08-01 2024-07-31 10289696 frs-bus:SmallEntities 2023-08-01 2024-07-31 10289696 frs-bus:AuditExempt-NoAccountantsReport 2023-08-01 2024-07-31 10289696 frs-bus:SmallCompaniesRegimeForAccounts 2023-08-01 2024-07-31 10289696 frs-bus:OrdinaryShareClass1 2023-08-01 2024-07-31 10289696 frs-bus:OrdinaryShareClass1 2024-07-31 10289696 frs-bus:Director1 2023-08-01 2024-07-31 10289696 frs-countries:EnglandWales 2023-08-01 2024-07-31 10289696 2022-07-31 10289696 2023-07-31 10289696 2022-08-01 2023-07-31 10289696 frs-core:CurrentFinancialInstruments 2023-07-31 10289696 frs-core:ShareCapital 2023-07-31 10289696 frs-core:RetainedEarningsAccumulatedLosses 2023-07-31 10289696 frs-bus:OrdinaryShareClass1 2022-08-01 2023-07-31
Registered number: 10289696
Immune Insight Limited
Unaudited Financial Statements
For The Year Ended 31 July 2024
Deans
Gibson House Hurricane Court
Hurricane Close
Stafford
ST16 1GZ
Contents
Page
Balance Sheet 1—2
Notes to the Financial Statements 3—4
Page 1
Balance Sheet
Registered number: 10289696
2024 2023
Notes £ £ £ £
FIXED ASSETS
Tangible Assets 4 1,015 1,624
1,015 1,624
CURRENT ASSETS
Debtors 5 12,810 11,344
Cash at bank and in hand 54,831 55,055
67,641 66,399
Creditors: Amounts Falling Due Within One Year 6 (13,027 ) (15,705 )
NET CURRENT ASSETS (LIABILITIES) 54,614 50,694
TOTAL ASSETS LESS CURRENT LIABILITIES 55,629 52,318
NET ASSETS 55,629 52,318
CAPITAL AND RESERVES
Called up share capital 7 1 1
Profit and Loss Account 55,628 52,317
SHAREHOLDERS' FUNDS 55,629 52,318
Page 1
Page 2
For the year ending 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board
Mrs M Cumberbatch
Director
16 January 2025
The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Notes to the Financial Statements
1. General Information
Immune Insight Limited is a private company, limited by shares, registered in England & Wales.  The company's registered number and registered office address can be found on the Company Information page.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of section 1a "Small Entities" and the Companies Act 2006.  The financial statements have been prepared under the historical cost convention.
The financial statements are presented in sterling which is the functional currency of the company and rounded to the nearest £.
The significant accounting policies applied in the preparation of these financial statements are set out below.  These policies have been consistently applied to all years presented unless otherwise stated.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of VAT and trade discounts.  The policies adopted for the recognition of turnover are as follows:
Rendering of services
When the outcome of a transaction can be measured reliably, turnover from medical research consultancy is recognised by reference to the stage of completion at the balance sheet date. Where the outcome cannot be measured reliably, turnover is recognised only to the extent of the expenses recognised that are recoverable.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are stated at cost less accumulated depreciation.  Cost includes costs directly attributable to making the asset capable of operating as intended.  Depreciation is provided at the following rates in order to write off each asset over its estimated useful life.
Computer Equipment 20% straight line
2.4. Leasing and Hire Purchase Contracts
Rentals payable and receivable under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.
2.5. Taxation
Taxation for the year comprises current and deferred tax.  Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.  
Current or deferred taxation assets and liabilities are not discounted.
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.  Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.
2.6. Debtors and creditors receivable / payable within one year
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price.  Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.
Page 3
Page 4
3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2023: 1)
1 1
4. Tangible Assets
Computer Equipment
£
Cost
As at 1 August 2023 2,030
Disposals (338 )
As at 31 July 2024 1,692
Depreciation
As at 1 August 2023 406
Provided during the period 271
As at 31 July 2024 677
Net Book Value
As at 31 July 2024 1,015
As at 1 August 2023 1,624
5. Debtors
2024 2023
£ £
Due within one year
Trade debtors 12,721 11,344
Prepayments and accrued income 89 -
12,810 11,344
6. Creditors: Amounts Falling Due Within One Year
2024 2023
£ £
Corporation tax 10,320 13,015
VAT 622 264
Accruals and deferred income 1,869 1,745
Director's loan account 216 681
13,027 15,705
7. Share Capital
2024 2023
Allotted, called up but not fully paid £ £
1 Ordinary Shares of £ 1.00 each 1 1
Page 4